

out to represent a key element in the Ca²⁺-dependent and lipid-raft-delineated switch that turned on activity-regulated dendrite formation in developing cortical neurons.

EXPERIMENTAL PROCEDURES

Cloning and Plasmid Constructions

A detailed description of all plasmids can be found in the Supplemental Data.

Immunocytochemistry

Cells were fixed in 4% paraformaldehyde/4% sucrose/phosphate-buffered saline (PBS) (–) at room temperature for 20 min, and immunostaining was carried out as described (Takemoto-Kimura et al., 2003). Additional methods can be found in the Supplemental Data.

Western Blot Analysis

For western blot analysis, primary antibodies were as follows: rat anti-GFP (Nacalai Tesque, Japan), rat anti-HA (Roche Diagnostics), mouse anti-Flotillin-1, mouse anti-Caveolin-2, and anti-Rac1 (BD Transduction Laboratories). A rabbit anti-STEF antibody was as described (Matsuo et al., 2002). Chemiluminescence detection was performed using HRP-conjugated anti-rat and anti-mouse IgG and ECL-Plus reagent (Amersham Biosciences).

Metabolic Labeling and Coimmunoprecipitation

For metabolic labeling, COS-7 cells plated onto 6-well plates were transfected with wild-type and mutant GFP-CL3 vectors using Fugene6 reagent (Roche Diagnostics). For mevalonate labeling, a pMev vector (ATCC), which encoded a transporter that augmented mevalonic acid uptake, was cotransfected with GFP-CL3 for 24 hr. Cells were pretreated with 40 μ M Compactin (Wako, Japan) for 2 hr, then incubated for 20 hr in growth medium supplemented with 40 μ M Compactin and 0.1 mCi/ml of [³H]-mevalonolactone (PerkinElmer or ARC). Palmitate labeling was initiated 48 hr after transfection by pretreating cells with serum-free medium (DMEM with 1% fatty-acid-free bovine serum albumin [Sigma]) for 1 hr, and then incubating for an additional 3 hr in the serum-free medium supplemented with 0.4 mCi/ml of [³H]-palmitic acid (PerkinElmer). After metabolic labeling, cells were washed twice in ice-cold phosphate-buffered saline (PBS) (–) and lysed in lysis buffer containing 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 2 mM MgCl₂, 10% glycerol, 1% Triton X-100, and a Complete protease inhibitor cocktail (Roche Diagnostics). Lysates were immunoprecipitated using a rabbit anti-GFP polyclonal antibody (Molecular Probes) and Protein-A-Sepharose (Amersham Biosciences). Immunoprecipitates were washed three times in lysis buffer and boiled in 4 \times Laemmli buffer containing 5 mM DTT for 3 min and were subjected to SDS-PAGE. Incorporated mevalonolactone and palmitic acid were digitally detected using a BAS-5000 bioimage analyzer and quantified using Multi Gauge software (Fujifilm, Japan).

In coimmunoprecipitation assays, cortical neurons were transfected with GFP-CL3 and HA-CL3 vectors by electroporation using Nucleofector (Amaxa Biosystems) and plated onto poly-D-Lysine-coated 6 cm dishes at the density of 4 \times 10⁵/cm² and then harvested at 2 DIV. Immunoprecipitation was performed as described above.

Lentivirus Production, Infection, and Lipid Raft Fractionation

A 536 bp synapsin I promoter was isolated by PCR from rat genomic DNA and inserted into CS-CA-MCS (Miyoshi et al., 1998) to replace the original chicken actin promoter. EGFP-CL3 fragment was further inserted and cotransfected with pCAG-HIVgp and pCMV-VSV-G-RSV-Rev into HEK293T cells using Fugene6 reagent to generate a self-inactivating lentivirus vector. All original lentivirus vectors were provided by Dr. Hiroyuki Miyoshi (RIKEN-BRC, Japan). Concentrated virus solutions were obtained by ultracentrifugation at 80,000 \times g, and virus titer was determined using HeLa cells. Cortical neurons

(1 DIV) were infected with lentivirus for 5 hr at a nominal MOI of about 0.2, and after washout, maintained in Neurobasal containing 0.5 mM Glutamax, 1 \times B27, and 25 μ g/ml insulin. Under these conditions, GFP-positive glial cells (as determined by GFAP expression) were less than 6%. Though the nominal MOI was about 0.2, this is very likely to be an underestimate, as it was calculated based on the induction of trace EGFP fluorescence in heterologous cells. Lipid raft preparations were performed 2 days after infection (3 DIV).

Lentivirus-infected cortical neurons in 10 cm dishes (3.5 \times 10⁵ cells/cm²) were harvested at 3 DIV for preparation of detergent-insoluble membrane fractions according to Suzuki et al. (2004) with minor modifications. Thirteen fractions (1 ml each) were collected and 15 μ l of each fraction were subjected to SDS-PAGE followed by western blot analysis. To obtain a concentrate of the raft fractions in Figure 5E, raft fractions (fractions 4 and 5) were pooled, and a portion of it (1.4 ml) was ultracentrifuged at 20,000 \times g for 1 hr at 4°C. The pellet was resuspended in 140 μ l of Buffer A (50 mM Tris-HCl [pH 7.5], 50 mM NaCl), and 15 μ l of the final sample was subjected to SDS-PAGE and western blot analysis.

Cell Culture Preparation and Visualization of Raft-Targeted Proteins

COS-7 cells were maintained in Dulbecco's modified Eagle medium (DMEM) containing 10% heat-inactivated fetal calf serum (FCS). Dissociated cortical cultures from embryonic day 19 Sprague-Dawley rats were prepared as described previously for rat hippocampal cultures (Bito et al., 1996) with minor modifications. Cortical neurons were plated onto 12 mm poly-L-Lysine-coated coverslips at the density of 5 \times 10⁵ cells per coverslip in a 24-well plate.

Gene targeting of CL3/CaMKI γ was carried out in a C57BL/6-derived ES cell line RENKA (Mishina and Sakimura, 2007) by insertional mutagenesis. The exons 2 and 3 of mouse the *Camk1g* gene, which contained the kinase ATP-binding site, were deleted and replaced by a targeting construct such that the first methionine of CL3 was fused in-frame to an hCrePR-IRES-EGFP cassette that was juxtaposed to an inverted neomycin resistance gene flanked by FRT sites. A detailed analysis of the CL3/CaMKI γ null mouse mutant will be described elsewhere (S.T.-K., M.O., T. Takeuchi, K. Sakimura, M.M., H.O., and H.B., unpublished data). Cortical mouse cultures were prepared from embryonic day 17 C57BL/6J wild-type or CL3 null mice.

For visualization of in situ raft-targeted GFP-fusion proteins, rat cortical or mouse hippocampal neurons were washed with KRH buffer (Suzuki et al., 2004) containing 2 mM Ca²⁺ on ice, permeabilized with 0.1% Triton X-100/KRH(+) for 2 min on ice, washed gently, and then fixed. Raft depletion in cortical neurons was carried out by including one of the following drugs (10 μ M mevastatin, 10 μ M fumonisin B₁, 10 μ M fumonisin B₁ and 10 μ M mevastatin, 100 μ M zaragozic acid, 100 μ M zaragozic acid, and 10 μ M mevastatin) in the culture medium from 6 hr after plating onward for an additional 42 hr. mRFP1 was nucleofected for accurate visualization of the contours of individual neurons.

In one instance, rat hippocampal neurons obtained from P0–1 Sprague-Dawley rats (Bito et al., 1996) were used to quantify FRET between CL3 molecules (Figure S2A).

Morphometric Analysis of the CL3-Associated Phenotype in Cultured Neurons

Dissociated cortical cultures from embryonic day 19 Sprague-Dawley rats were prepared as described previously for rat or mouse hippocampal cultures (Bito et al., 1996; Furuyashiki et al. 2002) with minor modifications. Cortical neurons were transfected immediately after dissociation by electroporation using Nucleofector and plated onto 12 mm poly-L-Lysine-coated coverslips at the density of 5 \times 10⁵ cells per coverslip (rats) or 7.5 \times 10⁵ cells per coverslip (mice) in 24-well plates, and then fixed at 2 DIV. Presumably because of a relatively low amount of plasmid transfer across neuronal membranes during electroporation procedure, use of a strong CAG promoter-driven expression cassette was needed to reliably express foreign genes.

Further, to unequivocally ascertain the phenotypes of neurons expressing various shRNA vectors and rescue constructs, we carried out all quantitative analyses based upon immunostaining of the morphometric markers, either GFP or mRFP1 (a kind gift from Dr. Roger Y. Tsien, HHMI, UCSD). This allowed us to obtain clearer images of neuronal contours, thus facilitating morphometric analyses. The transfection efficiency was relatively high (about 50% in our hands using this protocol) when examined within a day after electroporation. Thus, we were able to improve the accuracy of visualization in all morphometric experiments by simply mixing the transfected cells with nontransfected cells prepared in parallel, at a ratio of 1:20 (rats) or 1:10 (mice), before plating. Dendritic and axonal arborizations of most transfected neurons could then be traced in total isolation while they still formed a dense network with neighboring untransfected neurons. Neurons expressing pSUPER-type vectors revealed negligible amounts of either cell death (0%–0.5%) as measured by TUNEL staining (Roche Diagnostics) or dsRNA-induced interferon-like response monitored using a muMx2 promoter-luc vector (a kind gift from Dr. Atsushi Asano, Hokkaido University) (Alvarez et al., 2006).

In the Rac1-rescue experiments, even an intermediate-level expression of a constitutively active Rac mutant, GFP-V12Rac1, using a CAG promoter usually resulted in an aberrant neuronal morphology, such as exuberant lamellipodia formation at the cell soma and premature detachment from the glass coverslip. To circumvent this problem, GFP-V12Rac1 was introduced using a CMV promoter-based plasmid vector, as the observed expression level was lower than that obtained using a CAG promoter vector. A few neurons still showed an aberrant somata size and shape and thus were excluded from analyses.

Images of neuronal morphologies were captured based on immunoreactivities against GFP or mRFP1, using the Olympus BX51 microscopy system with the 20 \times objective or 40 \times objective in the cases of CL3-overexpression experiments to visualize fine protrusions for cumulative probability analysis. Dendrites and axons were identified by standard morphological criteria. As the majority of neurons, in our cortical culture preparation, possessed only one clearly classifiable axon and one or more dendrites, neurons with nonpyramidal morphological features (such as multiple axons or no classifiable processes) were excluded from analyses. The total length and the dendritic branch tip number were determined manually using NeuronJ 1.1.0 (Meijering et al., 2004), plug-in software for ImageJ (NIH). Representative images were acquired using the LSM 510META confocal microscope with the 40 \times objective. All analyses were performed by an observer blinded to the identity of the transfected constructs.

In experiments described in Figure S4, electroporated neurons were initially cultured as a suspension in a growth medium, without plating, in plastic centrifuge tubes at the density of 2×10^6 cells/ml, while neurons were allowed to form aggregation. Forty-eight hours later, aggregated neurons were then dissociated mechanically by gentle pipetting and plated onto 12 mm poly-L-Lysine-coated coverslips at the density of 1×10^6 cells per coverslip. Fixation and analysis were carried out 24 hr later.

Mouse hippocampal neurons were transfected using Lipofectamine 2000 (Invitrogen) at 7 DIV and analyzed at 9 DIV. Morphometric analyses of hippocampal neurons were performed as essentially described above for cortical neurons. Only primary dendrites were traced using ImageJ/NeuronJ software.

In Situ Hybridization

In situ hybridization using DIG technology (Roche Diagnostics) was performed essentially as described (Ohmae et al., 2006). For the generation of antisense and sense cRNA probes, a 374 bp fragment corresponding to the nucleotide position 964–1337 of CL3 was subcloned into pBluescriptII KS+ vector (Stratagene).

BDNF Application and Calcium Imaging in Cortical Neurons
BDNF (generously provided by Daiippon Sumitomo Pharma, Osaka, Japan, by courtesy of Dr. Chikao Nakayama) and/or KN-93 (Calbio-

chem) were added to cells at 6 hr after plating at the final concentration of 50 ng/ml and 10 μ M, respectively. Bath application was performed by dissolving the reagents in one-half volume of the conditioned culture medium and by mixing this gently with the remaining half of the original medium in the dish. No medium change was done thereafter till fixation.

Fluorescent calcium imaging was performed essentially as described previously (Furuyashiki et al., 2002). A detailed description of further experimental conditions can be found in the Supplemental Data.

Rac1 Pull-Down Assays, Measurement of Fluorescence Resonance Energy Transfer, and Quantification of Golgi Deformation

A detailed description of experimental procedures can be found in the Supplemental Data.

Statistical Analysis

Statistical analyses were performed using Prism 4.0 (GraphPad Software) and JMP5.1.2 (SAS Institute). Student's *t* test was used for comparisons of two groups. One- or two-way analysis of variance (ANOVA) with post hoc Tukey-Kramer or Bonferroni test was used for factorial analysis between more than three groups. The Kolmogorov-Smirnov test was applied to verify whether the bidirectional effect of CL3 manipulation occurred throughout all dendrites or was restricted to a subpopulation. All data are shown as mean \pm standard error of means (SEM), unless otherwise mentioned.

Supplemental Data

The Supplemental Data for this article can be found online at <http://www.neuron.org/cgi/content/full/54/5/755/DC1/>.

ACKNOWLEDGMENTS

We thank A. Asano, Z. Honda, Y. Ihara, A. Miyawaki, H. Miyoshi, S. Narumiya, F. Oyama, B. Sabatini, and R.Y. Tsien for providing plasmids; S. Wada, M. Morishima-Kawashima, and Y. Ihara for a raft fractionation protocol; T. Furuyashiki for generating EGFP-GluR1; K. Ohkubo for assistance with *in situ* hybridization; and all members of the Bito laboratory for discussion. We acknowledge the invaluable support of H. Mori in designing a successful targeting vector and of T. Takeuchi and K. Sakimura for an ongoing collaboration to generate and characterize CL3 null mice. We are also indebted to assistance from K. Salki, Y. Kondo, and T. Kinbara. This work was supported in part by Grants-in-Aid from the MEXT and MHLW of Japan, by a JST-SORST investigatorship, and by awards from the Astellas Foundation for Research on Metabolic Disorders, the Brain Science Foundation, the Cell Science Research Foundation, the Japan Foundation for Applied Enzymology, the Kowa Life Science Foundation, the Novartis Foundation (Japan) for the Promotion of Science, the Shimadzu Science Foundation, the Takeda Foundation, the Toray Science Foundation, and the Human Frontier Science Program. N.A.-I. and H.F. are predoctoral fellows, and M.N. is a postdoctoral fellow from the Japan Society for the Promotion of Science.

Received: May 23, 2006

Revised: December 30, 2006

Accepted: May 16, 2007

Published: June 6, 2007

REFERENCES

Alvarez, V.A., Ridenour, D.A., and Sabatini, B.L. (2006). Retraction of synapses and dendritic spines induced by off-target effects of RNA interference. *J. Neurosci.* 26, 7820–7825.

- Anderson, R.G.W., and Jacobson, K. (2002). A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. *Science* 296, 1821–1825.
- Bito, H., and Takemoto-Kimura, S. (2003). Ca²⁺/CREB/CBP-dependent gene regulation: a shared mechanism critical in long-term synaptic plasticity and neuronal survival. *Cell Calcium* 34, 425–430.
- Bito, H., Deisseroth, K., and Tsien, R.W. (1996). CREB phosphorylation and dephosphorylation: a Ca²⁺- and stimulus duration-dependent switch for hippocampal gene expression. *Cell* 87, 1203–1214.
- Ciani, L., and Salinas, P.C. (2005). WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. *Nat. Rev. Neurosci.* 6, 351–362.
- Cline, H.T. (2001). Dendritic arbor development and synaptogenesis. *Curr. Opin. Neurobiol.* 11, 118–126.
- Da Silva, J.S., Hasegawa, T., Miyagi, T., Dotti, C.G., and Abad-Rodriguez, J. (2005). Asymmetric membrane ganglioside sialidase activity specifies axonal fate. *Nat. Neurosci.* 8, 606–615.
- DeSouza, S., Fu, J., States, B.A., and Ziff, E.B. (2002). Differential palmitoylation directs the AMPA receptor-binding protein ABP to spines or to intracellular clusters. *J. Neurosci.* 22, 3493–3503.
- El-Husseini, A.E.-D., and Brecht, D.S. (2002). Protein palmitoylation: a regulator of neuronal development and function. *Nat. Rev. Neurosci.* 3, 791–802.
- Fan, Q.W., Yu, W., Gong, J.S., Zou, K., Sawamura, N., Senda, T., Yanagisawa, K., and Michikawa, M. (2002). Cholesterol-dependent modulation of dendrite outgrowth and microtubule stability in cultured neurons. *J. Neurochem.* 80, 178–190.
- Fink, C.C., Bayer, K.-U., Myers, J.W., Ferrell, J.J.E., Schulman, H., and Meyer, T. (2003). Selective regulation of neurite extension and synapse formation by the β - but not the α -isoform of CaMKII. *Neuron* 39, 283–297.
- Fox, K., and Wong, R.O. (2005). A comparison of experience-dependent plasticity in the visual and somatosensory systems. *Neuron* 48, 465–477.
- Fukata, M., Fukata, Y., Adesnik, H., Nicoll, R.A., and Brecht, D.S. (2004). Identification of PSD-95 palmitoylating enzymes. *Neuron* 44, 987–996.
- Furuyashiki, T., Arakawa, Y., Takemoto-Kimura, S., Bito, H., and Narumiya, S. (2002). Multiple spatiotemporal modes of actin reorganization by NMDA receptors and voltage-gated Ca²⁺ channels. *Proc. Natl. Acad. Sci. USA* 99, 14458–14463.
- Gaudilliere, B., Konishi, Y., de la Iglesia, N., Yao, G., and Bonni, A. (2004). A CaMKII-NeuroD signaling pathway specifies dendritic morphogenesis. *Neuron* 41, 229–241.
- Hayashi, T., Rumbaugh, G., and Haganir, R.L. (2005). Differential regulation of AMPA receptor subunit trafficking by palmitoylation of two distinct sites. *Neuron* 47, 709–723.
- Hering, H., Lin, C.C., and Sheng, M. (2003). Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. *J. Neurosci.* 23, 3262–3271.
- Higgins, D., Burack, M., Lein, P., and Banker, G. (1997). Mechanisms of neuronal polarity. *Curr. Opin. Neurobiol.* 7, 599–604.
- Hook, S.S., and Means, A.R. (2001). Ca²⁺/CaM-dependent kinases: from activation to function. *Annu. Rev. Pharmacol. Toxicol.* 41, 471–505.
- Horton, A.C., Racz, B., Monson, E.E., Lin, A.L., Weinberg, R.J., and Ehlers, M.D. (2005). Polarized secretory trafficking directs cargo for asymmetric dendrite growth and morphogenesis. *Neuron* 48, 757–771.
- Huang, E.J., and Reichardt, L.F. (2003). Trk receptors: roles in neuronal signal transduction. *Annu. Rev. Biochem.* 72, 609–642.
- Huang, K., and El-Husseini, A. (2005). Modulation of neuronal protein trafficking and function by palmitoylation. *Curr. Opin. Neurobiol.* 15, 527–535.
- Hudmon, A., and Schulman, H. (2002). Neuronal Ca²⁺/Calmodulin-dependent protein kinase II: the role of structure and autoregulation in cellular function. *Annu. Rev. Biochem.* 71, 473–510.
- Jan, Y.-N., and Jan, L.Y. (2003). The control of dendrite development. *Neuron* 40, 229–242.
- Kawauchi, T., Chihama, K., Nabeshima, Y., and Hoshino, M. (2003). The in vivo roles of STEF/Tiam1, Rac1 and JNK in cortical neuronal migration. *EMBO J.* 22, 4190–4201.
- Keller, C.A., Yuan, X., Panzanelli, P., Martin, M.L., Alldred, M., Sassoe-Pognetto, M., and Luscher, B. (2004). The gamma2 subunit of GABA_A receptors is a substrate for palmitoylation by GODZ. *J. Neurosci.* 24, 5881–5891.
- Kennedy, M.B. (2000). Signal-processing machines at the postsynaptic density. *Science* 290, 750–754.
- Konur, S., and Ghosh, A. (2005). Calcium signaling and the control of dendritic development. *Neuron* 46, 401–405.
- Kozorovitskiy, Y., Gross, C.G., Kopil, C., Battaglia, L., McBreen, M., Stranahan, A.M., and Gould, E. (2005). Experience induces structural and biochemical changes in the adult primate brain. *Proc. Natl. Acad. Sci. USA* 102, 17478–17482.
- Kuhn, T.B., Williams, C.V., Dou, P., and Kater, S.B. (1998). Laminin directs growth cone navigation via two temporally and functionally distinct calcium signals. *J. Neurosci.* 18, 184–194.
- Kumanogoh, H., Miyata, S., Sokawa, Y., and Maekawa, S. (2001). Biochemical and morphological analysis on the localization of Rac1 in neurons. *Neurosci. Res.* 39, 189–196.
- Linder, M.E., and Deschenes, R.J. (2004). Model organisms lead the way to protein palmitoyltransferases. *J. Cell Sci.* 117, 521–526.
- Lisman, J., Schulman, H., and Cline, H. (2002). The molecular basis of CaMKII function in synaptic and behavioural memory. *Nat. Rev. Neurosci.* 3, 175–190.
- Luo, L. (2002). Actin cytoskeleton regulation in neuronal morphogenesis and structural plasticity. *Annu. Rev. Cell Dev. Biol.* 18, 601–635.
- Matsuo, N., Hoshino, M., Yoshizawa, M., and Nabeshima, Y. (2002). Characterization of STEF, a guanine nucleotide exchange factor for Rac1, required for neurite growth. *J. Biol. Chem.* 277, 2860–2868.
- Meijering, E., Jacob, M., Sarria, J.C., Steiner, P., Hirling, H., and Unser, M. (2004). Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy images. *Cytometry A* 58, 167–176.
- Mishina, M., and Sakimura, K. (2007). Conditional gene targeting on the pure C57BL/6 genetic background. *Neurosci. Res.*, in press. Published online January 18, 2007. 10.1016/j.neures.2007.01.004.
- Miyoshi, H., Blomer, U., Takahashi, M., Gage, F.H., and Verma, I.M. (1998). Development of a self-inactivating lentivirus vector. *J. Virol.* 72, 8150–8157.
- Nishimura, H., Sakagami, H., Uezu, A., Fukunaga, K., Watanabe, M., and Kondo, H. (2003). Cloning, characterization and expression of two alternatively splicing isoforms of Ca²⁺/calmodulin-dependent protein kinase I gamma in the rat brain. *J. Neurochem.* 85, 1216–1227.
- Ohmae, S., Takemoto-Kimura, S., Okamura, M., Adachi-Morishima, A., Nonaka, M., Fuse, T., Kida, S., Tanji, M., Furuyashiki, T., Arakawa, Y., et al. (2006). Molecular identification and characterization of a family of kinases with homology to Ca²⁺/calmodulin-dependent protein kinases I/IV. *J. Biol. Chem.* 281, 20427–20439.
- Pelled, D., Riebeling, C., van Echten-Deckert, G., Sandhoff, K., and Futerman, A.H. (2003). Reduced rates of axonal and dendritic growth in embryonic hippocampal neurones cultured from a mouse model of Sandhoff disease. *Neuropathol. Appl. Neurobiol.* 29, 341–349.
- Redmond, L., Kashani, A.H., and Ghosh, A. (2002). Calcium regulation of dendritic growth via CaM Kinase IV and CREB-mediated transcription. *Neuron* 34, 999–1010.

- Schmitt, J.M., Wayman, G.A., Nozaki, N., and Soderling, T.R. (2004). Calcium activation of ERK mediated by calmodulin kinase I. *J. Biol. Chem.* 279, 24064–24072.
- Schmitt, J.M., Guire, E.S., Saneyoshi, T., and Soderling, T.R. (2005). Calmodulin-dependent kinase kinase/calmodulin kinase I activity gates extracellular-regulated kinase-dependent long-term potentiation. *J. Neurosci.* 25, 1281–1290.
- Schwarz, A., and Futerman, A.H. (1998). Inhibition of sphingolipid synthesis, but not degradation, alters the rate of dendrite growth in cultured hippocampal neurons. *Brain Res. Dev. Brain Res.* 108, 125–130.
- Silva, A.J., Kogan, J.H., Frankland, P.W., and Kida, S. (1998). CREB and memory. *Annu. Rev. Neurosci.* 21, 127–148.
- Soderling, T.R., and Stull, J.T. (2001). Structure and regulation of calcium/calmodulin-dependent protein kinases. *Chem. Rev.* 101, 2341–2352.
- Suzuki, T., Ito, J., Takagi, H., Saitoh, F., Nawa, H., and Shimizu, H. (2001). Biochemical evidence for localization of AMPA-type glutamate receptor subunits in the dendritic raft. *Brain Res. Mol. Brain Res.* 89, 20–28.
- Suzuki, S., Numakawa, T., Shimazu, K., Koshimizu, H., Hara, T., Hatanaka, H., Mei, L., Lu, B., and Kojima, M. (2004). BDNF-induced recruitment of TrkB receptor into neuronal lipid rafts: roles in synaptic modulation. *J. Cell Biol.* 167, 1205–1215.
- Takemoto-Kimura, S., Terai, H., Takamoto, M., Ohmae, S., Kikumura, S., Segi, E., Arakawa, Y., Furuyashiki, T., Narumiya, S., and Bito, H. (2003). Molecular cloning and characterization of CLICK-III/CaMKI γ , a novel membrane-anchored neuronal Ca²⁺/calmodulin-dependent protein kinase (CaMK). *J. Biol. Chem.* 278, 18597–18605.
- Tolias, K.F., Bikoff, J.B., Burette, A., Paradis, S., Harrar, D., Tavazoie, S., Weinberg, R.J., and Greenberg, M.E. (2005). The Rac1-GEF Tiam1 couples the NMDA receptor to the activity-dependent development of dendritic arbors and spines. *Neuron* 45, 525–538.
- Uemura, T., Mori, H., and Mishina, M. (2002). Isolation and characterization of Golgi apparatus-specific GODZ with the DHHC zinc finger domain. *Biochem. Biophys. Res. Commun.* 296, 492–496.
- Vaillant, A.R., Zanassi, P., Walsh, G.S., Aumont, A., Alonso, A., and Miller, F.D. (2002). Signaling mechanisms underlying reversible, activity-dependent dendrite formation. *Neuron* 34, 985–998.
- Van Aelst, L., and Cline, H.T. (2004). Rho GTPases and activity-dependent dendrite development. *Curr. Opin. Neurobiol.* 14, 297–304.
- Wassif, C.A., Zhu, P., Kratz, L., Krakowiak, P.A., Battaile, K.P., Weight, F.F., Grinberg, A., Steiner, R.D., Nwokoro, N.A., Kelley, R.I., et al. (2001). Biochemical, phenotypic and neurophysiological characterization of a genetic mouse model of RSH/Smith-Lemli-Opitz syndrome. *Hum. Mol. Genet.* 10, 555–564.
- Wayman, G.A., Kaech, S., Grant, W.F., Davare, M., Impey, S., Tokumitsu, H., Nozaki, N., Banker, G., and Soderling, T.R. (2004). Regulation of axonal extension and growth cone motility by calmodulin-dependent protein kinase I. *J. Neurosci.* 24, 3786–3794.
- Wayman, G.A., Impey, S., Marks, D., Saneyoshi, T., Grant, W.F., Derkach, V., and Soderling, T.R. (2006). Activity-dependent dendritic arborization mediated by CaM-kinase I activation and enhanced CREB-dependent transcription of Wnt-2. *Neuron* 50, 897–909.
- Whitford, K.L., Dijkhuizen, P., Polleux, F., and Ghosh, A. (2002). Molecular control of cortical dendrite development. *Annu. Rev. Neurosci.* 25, 127–149.
- Wu, G.-Y., and Cline, H.T. (1998). Stabilization of dendritic arbor structure in vivo by CaMKII. *Science* 279, 222–226.
- Yu, X., and Malenka, R.C. (2003). Beta-catenin is critical for dendritic morphogenesis. *Nat. Neurosci.* 6, 1169–1177.
- Zacharias, D.A., Violin, J.D., Newton, A.C., and Tsien, R.Y. (2002). Partitioning of lipid-modified monomeric GFPs into membrane microdomains of live cells. *Science* 296, 913–916.
- Zheng, J.Q., Felder, M., Connor, J.A., and Poo, M.M. (1994). Turning of nerve growth cones induced by neurotransmitters. *Nature* 368, 140–144.

THE CELLULAR AND BEHAVIORAL CONSEQUENCES OF INTERLEUKIN-1 ALPHA PENETRATION THROUGH THE BLOOD–BRAIN BARRIER OF NEONATAL RATS: A CRITICAL PERIOD FOR EFFICACY

M. TOHMI,^a N. TSUDA,^a Y. ZHENG,^b M. MIZUNO,^d
H. SOTOYAMA,^a M. SHIBUYA,^a M. KAWAMURA,^a
A. KAKITA,^c H. TAKAHASHI^b AND H. NAWA^{a,d*}

^aDivision of Molecular Neurobiology, Brain Research Institute, Niigata University, Niigata 951-8585, Japan

^bDivision of Neuropathology, Brain Research Institute, Niigata University, Niigata 951-8585, Japan

^cBrain Resource Center, Brain Research Institute, Niigata University, Niigata 951-8585, Japan

^dCenter for Transdisciplinary Research, Niigata University, Niigata 951-2181, Japan

Abstract—Proinflammatory cytokines circulating in the periphery of early postnatal animals exert marked influences on their subsequent cognitive and behavioral traits and are therefore implicated in developmental psychiatric diseases such as schizophrenia. Here we examined the relationship between the permeability of the blood–brain barrier to interleukin-1 alpha (IL-1 α) in neonatal and juvenile rats and their later behavioral performance. Following s.c. injection of IL-1 α into rat neonates, IL-1 α immunoreactivity was first detected in the choroid plexus, brain microvessels, and olfactory cortex, and later diffused to many brain regions such as neocortex and hippocampus. In agreement, IL-1 α administration to the periphery resulted in a marked increase in brain IL-1 α content of neonates. Repeatedly injecting IL-1 α to neonates triggered astrocyte proliferation and microglial activation, followed by behavioral abnormalities in startle response and putative prepulse inhibition at the adult stage. Analysis of covariance with a covariate of startle amplitude suggested that IL-1 α administration may influence prepulse inhibition. However, adult rats treated with IL-1 α as neonates exhibited normal learning ability as measured by contextual fear conditioning, two-way passive shock avoidance, and a radial maze task and had no apparent sign of structural abnormality in the brain. In comparison, when IL-1 α was administered to juveniles, the blood–brain barrier permeation was limited. The increases in brain IL-1 α content and immunoreactivity were less pronounced following IL-1 α administration and behavioral abnormalities were not manifested at the adult stage. During early development, therefore, circu-

lating IL-1 α efficiently crosses the blood–brain barrier to induce inflammatory reactions in the brain and influences later behavioral traits. © 2007 IBRO. Published by Elsevier Ltd. All rights reserved.

Key words: BBB, cytokine, IL-1, prepulse inhibition, sensorimotor gating, schizophrenia.

Obstetric complications as well as maternal and perinatal viral infection have been proposed to increase the risk of schizophrenia (O'Callaghan et al., 1991, 1992; Cannon et al., 2002). This hypothesis has been examined by challenging rodent dams or neonates with viral infection, hypoxia and asphyxia (Borrell et al., 2002; Fatemi et al., 2002a; Zuckerman et al., 2003; Shi et al., 2003). Infecting pregnant mice with influenza virus results in inflammatory reactions in the fetal body and brain although the virus is not detectable in the fetus (Shi et al., 2005). Non-vital viral and bacterial components, polyinosinic-polycytidylic acid and bacterial lipopolysaccharides, can produce similar maternal immune responses and the glial reaction in fetal brain without apparent neurodegeneration, and later induce various abnormal behaviors of offspring that are sensitive to antipsychotic medication (Urakubo et al., 2001; Fatemi et al., 2002b, 2005; Gayle et al., 2004; Meyer et al., 2006a). Thus, immune inflammatory responses, rather than viral cytotoxicity, play a central role in perturbing brain development including aspects that contribute to later neurobehavioral traits.

The fetal and neonatal immune inflammatory reactions following viral challenge or hypoxia include induction of various proinflammatory cytokines that are implicated in the etiology or neuropathology of schizophrenia (Nawa and Takei, 2006). Maternal challenge with polyinosinic-polycytidylic acid and neonatal exposure to Borna virus strongly induce interleukin (IL)-1 β in fetal body and tumor necrosis factor (TNF) α in neonates, respectively (Hornig et al., 1999; Watanabe et al., 2003; Meyer et al., 2006b,c). These proinflammatory cytokines are markedly induced in human fetal amniotic fluids following obstetric complications or abnormal pregnancy (Romero et al., 1990; Halgunset et al., 1994). Thus embryos and newborns can be exposed to high concentrations of proinflammatory cytokines depending on the severity of labor and the term of pregnancy (Tsunoda et al., 1990; Sarandakou et al., 1998). While cytokine-mediated intra-placental inflammation has been implicated in abnormal brain development and impaired brain function later in life (Muller and Acken-

*Correspondence to: H. Nawa, Division of Molecular Biology, Brain Research Institute, Niigata University, Asahimachi-dori 1-757, Niigata 951-8585, Japan. Fax: +81-25-227-0815.

E-mail address: hnawa@bri.niigata-u.ac.jp (H. Nawa).

Abbreviations: ANCOVA, analysis of covariance; BBB, blood–brain barrier; CS, conditioned stimulus; EDTA, ethylenediaminetetraacetic acid; ED-1, ectodysplasin 1; EGF, epidermal growth factor; EIA, enzyme immunoassay; GAD, glutamic acid decarboxylase; GFAP, glial fibrillary acidic protein; IL-1, interleukin-1; NCAM, neural cell adhesion molecule; PBS, phosphate-buffered saline; PND, postnatal day; PPI, prepulse inhibition; TH, tyrosine hydroxylase; TNF, tumor necrosis factor; US, unconditioned stimulus.

0306-4522/07\$30.00+0.00 © 2007 IBRO. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.neuroscience.2007.08.034

heil, 1998; Nawa et al., 2000), it is not clear how cytokines in the periphery penetrate the blood–brain barrier (BBB) and act on immature neurons or glial cells in the brain.

IL-1 is a proinflammatory cytokine that mediates stress and inflammatory responses in the immune, endocrine, and nervous systems (Minami et al., 1991, 1992; Rothwell and Luheshi, 2000). Infection, hypoxia and tissue injury all induce the production of IL-1 α and/or IL-1 β in the periphery, both of which bind to and activate the same receptor (Rothwell and Luheshi, 2000). In this context, IL-1 is one of the proinflammatory cytokines that are commonly involved in schizophrenia risk events such as maternal viral infection and obstetric complications (Nawa and Takei, 2006). Although IL-1 α and IL-1 β have limited access to the CNS in adults (McLay et al., 2000; Banks et al., 2002–2003), the perinatal or early postnatal impact of IL-1 in the periphery appears to be more dynamic and prolonged (Tohmi et al., 2004; Tsuda et al., 2006). In previous studies, we s.c. treated rat pups with similar high doses of the proinflammatory cytokines, epidermal growth factor (EGF), IL-1 α , IL-2, IL-6, interferon γ , and leukemia inhibitory factor, and found that, among the cytokines tested, only EGF and IL-1 α exhibit the severe and persistent influence on prepulse inhibition (PPI), social interaction, exploratory behaviors and acoustic responses (Futamura et al., 2003; Watanabe et al., 2004; Tohmi et al., 2004; Tsuda et al., 2006). In addition, genetic and brain imaging studies on schizophrenia also indicate a tight link between IL-1 and this illness. Nucleotide polymorphism of the IL-1 gene complex is associated with a schizophrenia risk, potentially contributing to ventricular enlargement of schizophrenia patients (Katila et al., 1999; Papiol et al., 2005). Despite evidence implicating IL-1 as one of the factors that can modulate neurobehavioral development and are implicated in schizophrenia etiology or pathology, molecular and cellular influences of circulating IL-1 α in developing brain are largely unknown.

In the present study, we s.c. administered human recombinant IL-1 α to rats at neonatal and juvenile stages. Permeation of IL-1 α was estimated by immunohistochemistry and enzyme immunoassay (EIA) for human IL-1 α in the acute phase and following repeated IL-1 α injections by glial responses in a subchronic phase. To assess the consequences of IL-1 α penetrance through neonatal BBB on later brain function, we examined the behavioral performance of these rats as adults. The permeability of the BBB to IL-1 α was compared at neonatal and juvenile ages and correlated with the behavioral deficits elicited by administration of this cytokine.

EXPERIMENTAL PROCEDURES

Animals and cytokine treatment

Newborn Sprague–Dawley rats (all male, 12 litters total; SLC, Shizuoka, Japan) were obtained at postnatal day (PND) 2. We minimized the number of animals used and their suffering. Litters were designated born on PND1 and culled to 10 male pups by the vendor. Rats were housed with their dam in polypropylene cages (58L×28W×24H cm) in a temperature-controlled colony room maintained on a 12-h light/dark cycle (light on 08:00 h). Recom-

binant human IL-1 α (1.0 μ g/g body weight; Dainippon Pharmaceuticals, Osaka, Japan) or vehicle (phosphate-buffered saline; PBS) was administered s.c. to rats daily at the nape of the neck during PNDs PND2 to PND10 or PND14 to PND22. In our preliminary study, lower doses of recombinant human IL-1 α (0.3, 0.1, and 0.01 μ g/g body weight) failed to affect behavioral traits (Fig. 1 in a supplement). Thus, we gave neonatal rats the dose of 1.0 μ g IL-1 α /g body that caused mild weight loss but not lethality (Tohmi et al., 2004). At PND22–25, pups were weaned and separated into cage (three to four animals per cage). Two litters of rats were assigned to each behavioral test and not reused in other behavioral tests. Tests were performed during the night cycle (20:00–02:00 h). In a second set of experiments, IL-1 α (1.0 μ g/g) or PBS was injected s.c. into rat pups (PND2 or PND14) to examine acute effects on intracellular signaling. Food and water were available *ad libitum* except for rats tested with the radial maze task. These animals were limited to 10 g of food per day during the maze task. All animal protocols were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Animal Use and Care Committee of Niigata University.

EIA

Postnatal rats (PND2 and PND14) were given an s.c. injection of human recombinant IL-1 α (1.0 μ g/g body weight). One h or 4 h after injection rats were subjected to hypothermia and then transcardially perfused with cold PBS (10 ml for PND2 and 30 ml for PND14) to wash out IL-1 α remaining in blood vessels. To estimate the amount of human IL-1 α penetrating the BBB, the frontal cortex including the anterior cingulate was taken and homogenized in 10 volumes of homogenization buffer containing 1% Triton X-100 and protease inhibitors [aprotinin (200 kallikrein U/ml), 0.1 mM phenylmethylsulfonyl fluoride, 0.1 mM benzethonium chloride, 1 mM benzamidine (all, Sigma Chemical Co., St. Louis, MO, USA), and 1 mM EDTA] (Nawa et al., 1995). Brain homogenates were centrifuged at 14,000 \times g for 30 min at 4 $^{\circ}$ C and the supernatants were stored at –80 $^{\circ}$ C until use. Protein concentrations in the samples were determined using a Micro BCA kit (Pierce, Rockland, IL, USA) with bovine serum albumin as a standard. IL-1 α levels were measured by a sandwich EIA kit for this cytokine (Cayman Chemical, Ann Arbor, MI, USA), as described in a manufacturer's protocol. The secondary antibody directed against human IL-1 α was conjugated to acetylcholinesterase. The acetylcholinesterase activity retained in each well was measured by incubation with Ellman's reagent. The amount of the resulting yellow product was monitored by a plate reader with 450 nm light. EIA had a minimum dynamic range of 5–250 pg/well.

Immunoblot analysis

To evaluate the subchronic influence of IL-1 α on neuroinflammatory markers, protein samples were prepared from IL-1 α -treated animals 24 h after the last of multiple cytokine injections. Protein (5 μ g or 50 μ g/lane) was subjected to 8% or 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. The membrane was probed with antibodies directed against Iba1 neural cell adhesion molecule (NCAM, 1:5000, Sigma), glial fibrillary acidic protein (GFAP, 1:5000, Dako, Tokyo, Japan), D1 dopamine receptor (1:1000), D2 dopamine receptor (1:1000), AMPA receptor subunit GluR1 (1:1000), type 1 NMDA receptor (NR1, 1:1000), glutamic acid decarboxylase 67 (GAD; 1:500), tyrosine hydroxylase (TH; 1:1000), synaptophysin (1:1000), and synapsin I (1:800) (all from Chemicon, Temecula, CA, USA). Primary antibodies were detected with appropriate secondary antibodies and chemiluminescence (Amersham-Pharmacia, Tokyo, Japan).

Brain histology

To visualize brain distributions of IL-1 α following s.c. injection, neonatal (PND2) and juvenile rats (PND14) received an s.c. injection of IL-1 α (1.0 μ g/g body weight) or PBS. One h or 4 h after injection, rats were transcardially perfused with 4% paraformaldehyde and in a 0.1 M phosphate-buffered solution (pH 7.4). For neuropathological examination, alternatively, IL-1 α -treated and vehicle-treated rats (PND11 or PND60) were fixed with 4% paraformaldehyde and 0.1% glutaraldehyde in a 0.1 M phosphate-buffered solution (pH 7.4) by transcardial perfusion. Serial sections (4 and 10 μ m thick) were cut from paraffin-embedded or frozen tissues, stained with hematoxylin and eosin or Klüver-Barrera stain. Alternatively, brain sections were incubated with antibodies directed against human IL-1 α (1:100, Chemicon), GFAP (1:500, Dako) and ectodysplasin 1 (ED-1, 1:50, Serotec, Oxford, UK) subsequently stained using the ABC method (Vector Laboratories, Burlingame, CA, USA).

Measurement of acoustic startle and PPI

Startle amplitude and PPI responses were assessed in a startle chamber (SR-LAB Startle Response System, San Diego Instrument, San Diego, CA, USA) with 120-dB acoustic stimuli, a single 100-ms prepulse interval, and three different prepulse intensities [5, 10, and 15 dB above background noise (white noise, 70 dB)]. Depending on the animal's mass, the sensitivity of the startle chamber was adjusted to obtain a linear dynamic range by setting the amplitude of the vibrator to 250 units for 4 week-old rats and 125 units for 8 week-old rats (arbitrary unit measure of this machine). This twofold difference in sensitivity was normalized after data acquisition. PPI was determined with the following two calculations: The percentage reduction in startle amplitudes following prepulse stimuli (% PPI) was calculated as: $100 - [(\text{startle response on prepulse-pulse stimulus trials} - \text{no stimulus trials}) / (\text{pulse-alone trials} - \text{no stimulus trials}) \times 100]$ (Braff and Geyer, 1990; Swerdlow and Geyer, 1998). The absolute reduction from pulse-alone startle amplitudes (absolute PPI) was calculated as: $\text{pulse-alone trials} - \text{startle response on prepulse-pulse stimulus trials}$ (Grillon et al., 1992).

Active-avoidance learning

Rats were given 10 sessions of two-way active-avoidance conditioning (10 trials/day). Active-avoidance testing was conducted in a two-way automated shuttle box (Muromachi-kiki, Tokyo, Japan). The conditioned stimulus (CS) was an 80-dB tone for 5 s. The unconditioned stimulus (US), a 5-s positive half-wave constant current of 0.6-mA intensity, was initiated if the animal failed to make an escape response (crossing to the other side of the shuttle box). The inter-trial interval was variable (20–40 s; Futamura et al., 2003).

Contextual conditioning

Rats were habituated in a test chamber (30L \times 30W \times 90H cm box; Muromachi-kiki) for 5 min and exposed to 0.8-mA electric shocks (2 s, twice). One day after conditioning, rats were returned to the chamber. The time spent freezing (i.e. no movements except those necessary for respiration) was counted at 1-min intervals for 3 min. Freezing behavior was recorded by a video camera during all sessions (Ohno et al., 2001).

Radial arm maze task

The radial arm maze contained eight arms (48 \times 12 cm) extending radially from a central area (32 cm in diameter) with a 5-cm edge around the apparatus (Neuroscience Inc., Tokyo, Japan). Each animal was subjected to a reference and working memory task for 15 days (three sessions/day) during which the same four arms

were baited for each daily training session (Mizuno et al., 2000). The other four arms were never baited. The training trial continued until four baits had been consumed or until 5 min had elapsed. The number of reference memory errors (entering an arm that was not baited) was counted.

Statistical analysis

Results were expressed as means \pm S.E.M. Startle response, PPI, and learning measures were analyzed using ANOVA with repeated measures, followed by a Tukey post hoc test for groups having similar deviations or a Games-Howell post hoc test for groups having different deviations. In repeated measures ANOVA, a between subject factor was treatment (IL-1 and PBS) and a within subject factor was either test session or prepulse intensity of absolute or percentage reduction of startle amplitudes. A Pearson's correlation test between pulse-alone startle responses and PPI levels was performed, followed by analysis of covariance (ANCOVA) with a subject factor of treatment and a covariate of an absolute amount of pulse-alone startle. To quantify immunoreactivity on blots, the densitometry of bands (arbitrary units) was performed and subjected to two-way ANOVA with subject factors of treatment and age or univariate analysis of Student's *t*-test for data at a single age. *N* values represent the number of animals. A *P* value of less than 0.05 was considered statistically significant. Statistical analysis was performed using the SPSS software (version 11.5; SPSS Japan Inc., Tokyo, Japan).

RESULTS

IL-1 α crosses the BBB in neonates

To assess the permeability of the BBB to IL-1 α in neonatal and juvenile rats, we examined brain distributions of human IL-1 α following peripheral administration of this cytokine (Figs. 1–3). One h after s.c. administration of IL-1 α , immunoreactivity for human IL-1 α was predominantly distributed in the choroids plexus of the ventricles and microvessels in the brain (Fig. 1b–d). A significant numbers of cells in the olfactory cortex also became immunopositive for IL-1 α at this time point. In contrast, there was little IL-1 α immunoreactivity in the brain of vehicle-injected animals (Fig. 1a). Four h after IL-1 α injection, immunoreactivity for IL-1 α disappeared from the ventricles and microvessels (Fig. 2a) and moved to cell surfaces in the neocortical regions (Fig. 2b–d) as well as in the hippocampus and hypothalamus (data not shown). In particular, there was strong IL-1 α immunoreactivity in cingulate cortex and olfactory cortex (Fig. 2c). Following peripheral administration of human IL-1 α into juvenile rats, penetration of IL-1 α to the brain was limited. IL-1 α immunoreactivity in the brain was modest or negligible in IL-1 α -treated juvenile rats, compared with that in of IL-1 α -treated neonates (Fig. 3).

To confirm that the permeability of the BBB decreases during development, we similarly administered IL-1 α to the periphery of neonatal (PND2) and juvenile rats (PND14) and measured IL-1 α content in the frontal cortex including cingulate cortex 1 h and 4 h after injection (Fig. 4). To remove human IL-1 α remaining in bloodstream of the brain, rats were perfused with excess amounts of PBS before tissue dissection. ANOVA with subject factors of treatment (IL-1 α and PBS), time (1 h and 4 h) and age (PND2 and PND14) revealed significant main effects of IL-1 α treatment ($F(1,24)=43.8$, $P<0.001$) and age




Fig. 1. IL-1 α immunoreactivity in neonatal rat brain 1 h after s.c. injection. Sixty min after PBS (a) or human IL-1 α (b–d) was s.c. injected into neonatal rats (PND2), brains were fixed and immunostained with an antibody directed against anti-human IL-1 α . The higher magnification images of c (the lateral ventricle) and d (the olfactory cortex) correspond to the areas indicated by the open boxes in b, respectively. Arrowheads mark microvessels carrying IL-1 α immunoreactivity. The numbers indicate the length of scale bars (μ m). Note: the choroid plexus in other brain sections exhibited similar immunoreactivity for IL-1 α (data not shown).

($F(1,24)=11.8$, $P=0.002$). A post hoc analysis indicated that human IL-1 α content in neonatal rats (PND2) was higher than that in juvenile rats (PND14) at both time points. Thus, these results confirmed that peripheral IL-1 α permeates the brain through the BBB at the neonatal stage of rats more efficiently than in the juvenile stage.

Neuroinflammatory responses in the brain following repeated IL-1 α treatment

The neuropathological consequences of repeated IL-1 injections were examined at PND11 when 24 h passed after the last IL-1 α injection was performed. When neonatal rats received daily injections of IL-1 α nine times, its effects were widespread to various regions of the brain. Cells positive for GFAP (an astrocyte marker) and ED-1 (a microglia marker) were present not only in the cingulate cortex and olfactory cortex (Fig. 5e–h) but also in other brain regions such as neocortex and hippocampus (Fig. 2 in a supplement). Expression of these glial markers was not a consequence of cell death as histological examina-

tion revealed few signs of neurodegeneration (i.e. cytoplasmic shrinkage, vacuolization, chromatin condensation, etc.) in hematoxylin and eosin or Kluver-Barrera staining (Fig. 5a–d). The increase in immunoreactivity for GFAP and ED1 presumably reflects glial responses to IL-1 α rather than to secondary glial reactions following neurodegeneration (Bonni et al., 1997; Proescholdt et al., 2002). This widespread glial activation in early postnatal rats indicates that peripherally administered IL-1 α promotes inflammatory reactions in various types of glial cells of the CNS, although the IL-1 effect on neuronal degeneration was undetectable.

Neurochemical alterations after neonatal IL-1 α treatment

We quantified the subchronic effects of repeated peripheral IL-1 α injections on developing neurons and glial cells in three brain regions of rat pups: the frontal cortex (including the cingulate cortex), the striatum and the hippocampus. In agreement to the histological examination, immunoblotting also revealed the glial responses to IL-1 α :




Fig. 2. Diffusion of IL-1 α immunoreactivity into neonatal rat brain 4 h after s.c. injection. Four h after human IL-1 α was s.c. injected into neonatal rats (PND2), distributions of IL-1 α immunoreactivity were examined in the brain (a–d). The higher magnification images of b (the lateral ventricle), c (the cingulate cortex) and d (the olfactory cortex) correspond to the areas indicated by the open boxes in a, respectively. Arrowheads mark microvessels that lost IL-1 α immunoreactivity found in Fig. 1d. The numbers indicate the length of scale bars (μ m). Note: Diffusion of IL-1 α immunoreactivity to the hypothalamus was also found (data not shown).

GFAP levels were increased ($P < 0.001$, $n = 5$) in the frontal cortex following IL-1 α -treatments. In the same brain region, protein levels for TH, a rate-limiting enzyme for dopamine synthesis, increased 20% ($P = 0.017$, $n = 5$) whereas GAD67 levels decreased 19% following neonatal IL-1 α treatment ($P = 0.039$, $n = 5$) (Fig. 6). There was no detectable change in TH or GAD67 in the striatum and hippocampus (data not shown). In parallel, levels for dopamine receptors (D1 and D2) were significantly decreased ($P < 0.001$ for D1, $P = 0.048$ for D2, $n = 5$) in frontal cortex. A similar decrease in the expression of dopamine receptors was also detected in the striatum and hippocampus (data not shown). In contrast, the levels of neuronal markers (NCAM) as well as post-synaptic markers GluR1 and NR1 and pre-synaptic markers synaptophysin and synapsin I, were indistinguishable between groups in all brain regions examined ($P = 0.111$ – 0.921 , $n = 5$). At the adult stage when IL-1 α -treated rats grew up, we did not detect significant changes in any of the neuronal and astroglial markers examined, suggesting the temporal limitation of the neu-

roinflammatory reactions following neonatal treatment with IL-1 α (data not shown).

Abnormal sensorimotor gating following neonatal IL-1 α administration

IL-1 α or saline (vehicle) was administered daily to littermates of neonatal rats (PND2) for 9 days as described above. Startle responses to a 120-dB tone in the presence and absence of the prepulse stimuli (none, 75-dB, 80-dB, and 85-dB tones) were monitored at 4 and 8 weeks of age ($n = 15$ each). The effects of neonatal IL-1 α administration on sensorimotor gating were mathematically evaluated as the percentage and the absolute reduction in startle magnitudes obtained with prepulse stimuli compared with trials without these prepulses (abbreviated to % PPI and absolute PPI, respectively) (Grillon et al., 1992; Cadenhead et al., 1993; Swerdlow et al., 2000), as the pulse-alone startle was affected by IL-1 α treatment (see below).

In young rats at 4 weeks of age, the absolute startle magnitudes were analyzed by repeated measures ANOVA




Fig. 3. Limited diffusion of IL-1 α immunoreactivity into juvenile rat brain following s.c. injection. Human IL-1 α was s.c. injected into juvenile rats (PND14), and distributions of IL-1 α immunoreactivity were examined in the brain 1 h (a) and 4 h after injection (b–d). The higher magnification images of c (the cingulate cortex) and d (the olfactory cortex) correspond to the areas indicated by the open boxes in b, respectively. The numbers indicate the length of scale bars (μ m).

with a between subject factor of treatment (IL-1 α and vehicle) and a within subject factor of prepulse amplitude (none, 75, 80, and 85 dB) (Fig. 7a). There was no significant main effect of IL-1 α treatment on the magnitude of the startle response ($F(1,28)=0.33$, $P=0.57$, repeated measures ANOVA) without interaction ($F(3,26)=1.17$, $P=0.39$, repeated measures ANOVA). Absolute PPI was not significantly altered by IL-1 α treatment ($F(1,28)=0.36$, $P=0.55$, repeated measures ANOVA) without interaction between IL-1 α treatment and prepulse ($F(2,27)=1.82$, $P=0.18$, repeated measures ANOVA) (Fig. 7b). In addition, IL-1 α had no significant effect on % PPI levels ($F(1,28)=0.97$, $P=0.33$, repeated measures ANOVA) without interaction ($F(3,27)=2.29$, $P=0.12$, repeated measures ANOVA) (Fig. 7c). Thus, we conclude that neonatal treatment with IL-1 α does not influence sensorimotor gating at the juvenile stage.

When we measured the startle amplitudes of these same rats in the presence and absence of prepulse stimuli at 8 weeks of age, the rats showed significant changes in absolute startle amplitudes (Fig. 7d). There was a main effect of IL-1 α treatment ($F(1,28)=16.5$, $P<0.001$) and an interaction of IL-1 α treatment and prepulse ($F(3,26)=4.31$, $P=0.0135$). Post hoc analysis detected significant increases in absolute startle amplitudes at all prepulse levels, as well as in the pulse-alone condition. To examine whether these differences only reflect the change in pulse-alone startle, we re-evaluated the data by calculating absolute PPI and % PPI. Repeated measures ANOVA for absolute PPI revealed no significant main effect of IL-1 α treatment ($F(1,28)=1.93$, $P=0.18$) but an interaction between IL-1 α treatment and prepulse ($F(2,27)=6.66$, $P=0.004$) (Fig. 7e). However, subsequent post hoc analysis failed to detect a significant difference between IL-1 α - and




Fig. 4. Brain IL-1 α content following s.c. administration to neonatal and juvenile rats. IL-1 α or PBS was s.c. injected into neonatal rats (PND2, $n=4$) and juvenile rats (PND14, $n=4$). One and 4 h after injection, IL-1 α remaining in blood vessels of the brain was washed out by cardiac perfusion of PBS and then the frontal cortex was taken. Protein content of human IL-1 α was measured by an EIA kit. Human IL-1 α levels were normalized by protein concentrations of tissue extracts. Post hoc; * $P<0.05$, compared between PND2 and PND14.

vehicle-treated groups at each prepulse level. When we calculated % PPI, we found significant effects of IL-1 α treatment (Fig. 7f). Ratio normalization with absolute pulse-alone startle decreased % PPI of the IL-1 α group ($F(1,28)=11.2$, $P=0.002$, repeated measures ANOVA) without an interaction of IL-1 α treatment \times prepulse ($F(3,27)=1.04$, $P=0.36$, repeated measures ANOVA). The explanation of the results from absolute PPI and % PPI is controversial with the given increase in pulse-alone startle (Swerdlow et al., 2000).

To examine how the increase in pulse-alone responses might affect values of absolute PPI and % PPI, data of individual animals were re-analyzed with the Pearson's correlation analysis and ANCOVA (Fig. 8) (Cadenhead et al., 1993). When the absolute magnitude of PPI for an 80-dB prepulse was plotted against the magnitude of the pulse-alone startle for each animal (Fig. 8a), there were strong linear correlations ($r=0.99$, $P<0.001$ for vehicle group and $r=0.91$, $P<0.001$ for IL-1 α group). There was a significant difference in the intercepts of the regression equations for vehicle and IL-1 α groups ($F(1,27)=-2.78$, $P=0.010$) but not in their slopes. Thus we performed ANCOVA with the pulse-alone values as covariates. The group main effect of IL-1 α treatment on absolute PPI was significant ($F(1,27)=9.88$, $P=0.004$, ANCOVA) toward the direction of reducing absolute PPI. Similar statistical results were obtained for the other prepulse intensities as well ($F(1,27)=4.83$, $P=0.037$ for 75 dB; $F(1,27)=4.56$, $P=0.041$ for 85 dB, both ANCOVA).

The data of % PPI for an 80-dB prepulse were also plotted against the absolute magnitude of the pulse-alone

startle (Fig. 8b). In the vehicle group, there was a correlation between pulse-alone startle and % PPI ($r=0.52$, $P=0.048$). There was a marginal trend toward a positive correlation between pulse-alone startle and % PPI in the IL-1 α group ($r=0.43$, $P=0.10$). Similar results were obtained for the other prepulse magnitudes (data not shown). These results suggest that neonatal IL-1 α treatment impairs acoustic startle responses and potentially sensorimotor gating at post-pubertal stages, assuming that the ANCOVA results are biologically meaningful. The putative abnormality in PPI scores was detected even at least 9 months of age in a separate group of animals (data not shown).

Delayed IL-1 α treatment at the juvenile stage and its influences

To test whether the neonatal administration of IL-1 α was critical for the later emergence of sensorimotor gating deficits, IL-1 α treatment was delayed for 12 days and performed at the juvenile stage (PND14–22). Levels of startle responses and sensorimotor gating were estimated with the absolute startle scale at 4 and 8 weeks of age (Fig. 9a–d). At 4 weeks of age, the absolute magnitude of startle was analyzed by repeated measures ANOVA with a between subject factor of treatment (IL-1 α and vehicle) and a within subject factor of prepulse magnitude (none, 75, 80, and 85 dB) (Fig. 9a). There was significant main effects of IL-1 α treatment ($F(1,18)=8.61$, $P=0.009$, repeated measures ANOVA) without factorial interactions ($F(2,17)=1.47$, $P=0.26$, repeated measures ANOVA).

The effects of IL-1 α were evaluated further with values of absolute PPI and % PPI. Absolute PPI levels for an 80-dB prepulse were significantly decreased by IL-1 α treatment ($F(1,18)=4.89$, $P=0.04$, repeated measures ANOVA) (Fig. 9c) whereas % PPI levels were not significantly altered ($F(1,18)=1.24$, $P=0.28$, repeated measures ANOVA) (Fig. 9b). As there were significant positive correlations between absolute PPI levels and pulse-alone startle in both groups, the effects of IL-1 α on absolute PPI were re-evaluated by ANCOVA with the pulse-alone values as covariates (Fig. 9d). ANCOVA revealed no significant effect of IL-1 α on absolute PPI ($F(2,17)=0.024$, $P=0.88$). Thus, the decrease in absolute PPI was superficial and may be attributed to the decrease in pulse-alone startle. Similar statistical results were obtained for the other prepulse magnitudes as well ($F(1,17)=0.16$, $P=0.69$ for 75 dB; $F(1,17)=1.30$, $P=0.27$ for 85 dB, both ANCOVA).

At week 8 of age, the startle responses, absolute PPI, and % PPI of these rats were re-examined (Fig. 10). Repeated measures ANOVA for absolute startle amplitudes, absolute PPI and % PPI did not detect any effects of IL-1 α treatment ($F(1,18)=1.24$, $P=0.28$; $F(1,18)=0.56$, $P=0.46$; $F(2,17)=1.47$, $P=0.26$, respectively) without interactions. Thus, we conclude that the long-term effects of IL-1 α on sensorimotor gating are less pronounced or negligible when this cytokine is administered to juvenile rats.




Fig. 5. Neuropathological alterations following repeated IL-1 α injections to rat neonates. IL-1 α or PBS was daily injected (s.c.) into neonatal rats from PND2 to PND10. Brain sections including the striatum and cingulate cortex were prepared from vehicle-treated (a, c, e, g) and IL-1 α -treated (b, d, f, h) rats at PND11 (24 h after the last IL-1 α administration) and examined for the Kluver-Barrera stain (KB; a, b), hematoxylin/eosin staining (HE; c, d), the astroglial marker, GFAP (e, f), and the microglial marker, ED-1 (g, h). Arrowheads indicate ED-1 immunoreactivity. Note: There were few signs of apoptosis or necrosis (cytoplasmic shrinkage, vacuolization, chromatin condensation) in both IL-1 α -treated and vehicle-treated rats. Scale bar=50 μ m.

Rats treated with IL-1 α display normal learning ability

To determine if the changes in PPI and acoustic startle response induced by IL-1 α treatment resulted from a general impairment of neural function, the learning ability of adult rats treated with IL-1 α as neonates was examined

with three learning paradigms; an active-avoidance test, contextual fear conditioning, and an eight-arm radial maze task. The active-avoidance test was performed in a two-way shuttle chamber with a buzzer sound (CS) and electric shock (US). There were no differences in the ability of vehicle- and IL-1 α -treated rats ($n=9$ each) to avoid an




Fig. 6. Effects of IL-1 α treatment on neurochemical markers in the frontal cortex. The subchronic effect of IL-1 α on the expression of neuronal and glial markers was examined in the frontal cortex of rat neonates by immunoblotting. Neonatal rats were similarly treated with IL-1 α or PBS from PND2 to PND10 and brain tissues were dissected out at PND11 when 24 h passes after the last injection were performed. Immunoblots were probed with the antibodies for a general neuronal marker, NCAM and an astroglial marker, GFAP. Neuronal markers specific for dopaminergic, GABAergic and glutamatergic neurons were also examined; TH, dopamine receptor 1 (D1), dopamine receptor 2 (D2), GAD67, AMPA-type glutamate receptor 1 (GluR1), NMDA-type glutamate receptor 1 (NR1), synaptophysin (SPHY), and synapsin I (SYNP) were compared between PBS-treated and IL-1 α -treated rat pups (PND11; $n=5$ animals each) by immunoblot analysis. (a) Two representative lanes in each group for all markers are shown for display. (b) Immunoreactivity on immunoblots was measured by densitometric analysis. Black bars represent ratios of immunoreactivity in IL-1 α -treated rats to that in control rats (mean \pm S.E.M.). * $P<0.05$, *** $P<0.001$.

electric shock after a tone stimulus during active-avoidance training ($F(1,16)=0.67$, $P=0.43$, repeated measures ANOVA) or in their ability to escape from electric shock ($F(1,16)=0.044$, $P=0.84$, repeated measures ANOVA; Fig. 11a). There was no factorial interaction between treat-

ment and training session. In the contextual conditioning test, an electric shock was given only in the test chamber. In this paradigm, freezing times between groups were indistinguishable before ($F(1,28)=1.03$, $P=0.320$, ANOVA) and after conditioning ($F(1,28)=0.761$, $P=0.391$, ANOVA; Fig. 11b). In the eight-arm radial maze task, rats were trained to learn the location of four baited arms. The IL-1 α -treated rats displayed normal rates of acquisition in spatial memory ($F(1,18)=0.796$, $P=0.384$, repeated measures ANOVA). There was no factorial interaction between IL-1 α treatment and training session (Fig. 11c). Thus, the gross learning ability of adult rats treated with IL-1 α -treated earlier in life was normal.

Neuropathological examination of adult rats treated with IL-1 α as neonates

To examine whether the observed behavioral changes accompanied neuropathological alterations, we examined histologically the brains of IL-1 α -treated rats, at the adult age (>PND60) when they exhibited the most pronounced neurobehavioral impairments. There was no indication of neuronal degeneration or structural alterations in any of the regions examined (Fig. 12a–h). Cortical structures were normal (Fig. 12a, b), and hippocampal pyramidal layers were intact in rats treated with IL-1 α as neonates (Fig. 12c, d). The striatum of IL-1 α -treated rats exhibited a normal organization (Fig. 12e, f). There were no significant differences in the molecular and granular layers of the cerebellum between IL-1 α - and vehicle-treated animals (Fig. 12g, h). These histological observations agree with the results from immunoblotting that there were no apparent decreases in any neuronal markers at the adult stage of the IL-1 α -treated animals.

DISCUSSION

In neonatal rats, peripheral IL-1 α efficiently penetrated the BBB and induced inflammatory reactions in early postnatal brain. The neuropathological changes triggered by IL-1 α were followed by abnormalities in startle responses and putative PPI at post-pubertal ages well after the initial inflammatory responses in the brain had subsided. In contrast to these behavioral abnormalities, the gross learning ability of IL-1 α -treated rats was normal. Although there was an apparent effect of neonatal exposure to IL-1 α on acoustic startle reaction, the abnormality in PPI is controversial and presumptive with the present results. The reason why we judge that the present data reflect PPI abnormality is because the following reports indicate dissociation between PPI and startle amplitudes in this animal model. An antipsychotic drug, clozapine, decreases PPI levels without affecting pulse-alone startle (Tohmi et al., 2004). In C57BL/6 mice, neonatal IL-1 α challenge alters PPI but not pulse-alone startle at the adult stage (Tsuda et al., 2006). In a critical sense, however, we cannot fully rule out the possibility that the putative PPI deficit of IL-1 α -treated rats might be in fact a reflection of their increased startle magnitude. The confirmation of the argument about




Fig. 7. Deficits in acoustic startle and PPI after neonatal IL-1 α treatment. (a, d) Absolute amplitudes of the 120-dB acoustic startle of rats treated with vehicle (open circle, $n=15$) and IL-1 α (closed circle, $n=15$) as neonates were monitored in the absence and presence of prepulse stimuli (none, 75, 80, and 85 dB) at 4 weeks of age (a) and 8 weeks of age (d). (b, e) Absolute magnitude of PPI was calculated as the absolute decrease from pulse-alone startle to prepulse-preceding startle and compared between vehicle-treated (open bars) and IL-1 α -treated (closed bars) animals at 4 (b) and 8 (e) weeks of age. (c, f) The percentage of the prepulse-preceding startle to pulse-alone startle (% PPI) was calculated and compared between groups at postnatal weeks 4 (c) and 8 (f). Absolute startle amplitudes are presented with an arbitrary unit of the acoustic startle machine made by SR-LAB Startle Response System (San Diego Instrument). Data represent means \pm S.E.M. (%). Post hoc; * $P < 0.05$, compared with vehicle-treated animals at the same age.




Fig. 8. Correlation analyses between absolute PPI and pulse-alone startle and between % PPI and pulse-alone startle. (a) Absolute magnitudes of PPI were plotted against the 120-dB pulse-alone acoustic startle of 8 week-old rats treated with vehicle (open circle, $n=15$) and IL-1 α (closed circle, $n=15$) as neonates. The data correspond to Fig. 7e. The slopes of the regression equations for vehicle and IL-1 α groups were similar ($F(1,26)=0.034$, $P=0.85$), but their intercepts were significantly different ($F(1,27)=-2.78$, $P=0.010$). (b) Percentage of PPI was calculated from the data of the same adult rats treated with vehicle (open circle, $n=15$) and IL-1 α (closed circle, $n=15$) as neonates and plotted against the pulse-alone startle. The data correspond to Fig. 7f. Note: There was no trend toward a decrease in the percentage of PPI versus absolute pulse-alone startle.

PPI deficit will require more elaborate biological analyses in future.

Both our previous and present studies failed to detect neurodegeneration following IL-1 α treatment in neonates (Tohmi et al., 2004) and adults (present data), despite evidence that IL-1 α may contribute to cytotoxic processes (Licinio and Wong, 1999; Rothwell and Luheshi, 2000). Thus, the immature brain is not fully protected from such

inflammatory cytokines generated in response to peripheral immune and inflammatory stress until the BBB is fully established. Acute administration of a variety of proinflammatory cytokines, such as IL-1, IL-2, IL-6, and TNF α , to adult animals is known to produce a set of depressive behaviors, namely sickness behavior (Anisman and Merali, 2003; Dantzer and Kelley, 2007). Sickness behaviors are different in quality and persistence from the behavioral impairments induced by neonatal IL-1 α treatment, however (Tohmi et al., 2004). For example, there was no decrease in locomotor activity of rats treated with IL-1 α as neonates. In addition, s.c. administration of all these inflammatory cytokines to neonates, even when the BBB is still leaky, does not produce such behavioral abnormalities at their adult stage. Among the proinflammatory cytokines examined (IL-1 α , IL-2, IL-6, TNF α , and interferon γ), only IL-1 α produces chronic behavioral impairments. These observations suggest that the biological activity of this particular cytokine has a crucial impact in determining the specificity and persistency of behavioral influences (Tohmi et al., 2004; Nawa and Takei, 2006).

The postnatal permeability of the BBB to IL-1 α appeared to be correlated with the later emergence of PPI abnormality in adult. IL-1 α administration during early development induced inflammatory reactions in the brain and led to the behavioral changes. S.c. injection of recombinant IL-1 α into neonates immediately increased brain content of this cytokine, suggesting that IL-1 α efficiently penetrates the neonatal BBB (McLay et al., 2000). In contrast, IL-1 α administration to juvenile rats resulted in the modest increase in IL-1 α content in the brain and did not produce later neurobehavioral impairments. These observations are consistent with a previous report that the BBB is immature and leaky at neonatal stages but fully develops around PND10 in rats (Kleshcheva, 1988). The leakiness of the BBB may not be a sole reason why IL-1 treatment in neonatal rats produced the behavioral alterations. It is possible that developmental plasticity of neonatal brain neurons and glia may additionally be required for the later emergence of the behavioral abnormality.

Among the neurochemical markers we examined, the increased TH and decreased dopamine receptor levels in the frontal cortex were noteworthy. Dopamine signaling may be involved in the PPI impairment we observed as deficits in sensorimotor gating are often correlated with dopaminergic dysfunction (Murphy et al., 1996; Jentsch et al., 1997; Swerdlow and Geyer, 1998). IL-1 is a potent differentiation factor for immature midbrain dopaminergic neurons and their precursors (Ling et al., 1998; Ho and Blum, 1997; Li et al., 2003) and this cytokine also increase the expression of GTP cycloase and enhance the production of BH4, rate limiting co-factor for TH (Pluss et al., 1996). Thus, neonatal IL-1 α treatment might accelerate aberrant development of dopaminergic neurons or trigger abnormal synapse formation of these neurons that persists into adulthood (Ho and Blum, 1998; Kim et al., 2002). Alternatively, glial cells, which were activated by IL-1 α , might produce the other cytokines or inflammatory mediators that perturb development of dopaminergic neurons or GABAergic




Fig. 9. Acoustic startle and PPI of 4-week-old rats following delayed IL-1 α treatment. Juvenile rats (PND14) s.c. received the same dose of IL-1 α or vehicle for 9 days. Compared with the neonatal treatment with IL-1 α , the treatment was delayed 2 weeks. (a) Absolute amplitudes of the 120-dB acoustic startle of rats treated with vehicle (open circle, $n=10$) and IL-1 α (closed circle, $n=10$) were measured in the absence and presence of prepulse stimuli (none, 75, 80, and 85 dB) at 4 weeks of age. (b) Percentage PPI was calculated and compared between the animals treated with vehicle and IL-1 α . (c) Absolute magnitudes of PPI were calculated as an absolute decrease from pulse-alone startle to prepulse-preceding startle and compared between the animals treated with vehicle (open bar) and IL-1 α (closed bar). Data represent means \pm S.E.M. Post hoc; * $P < 0.05$, compared with vehicle-treated animals at the same age. (d) Correlation analyzed between absolute PPI and pulse-alone startle at 4 weeks of age. The data correspond to those in Fig. 9c. Correlation of the data for vehicle-treated group (open circle) was significant ($r=0.78$, $P=0.007$) and that for IL-1 α -treated group (closed circle) was also significant ($r=0.79$, $P=0.007$). There was no significant difference in regression lines for IL-1 α -treated and vehicle-treated groups ($F(2,17)=0.024$, $P=0.88$). The slopes and intercepts of the regression equations were not significantly different between vehicle-treated and IL-1 α -treated groups ($F(1,16)=0.75$, $P=0.40$ for slope, $F(1,17)=0.010$, $P=0.92$ for intercept).

neurons. Another dopaminergic differentiation factor, EGF, is also known to increase TH levels in the neonatal brain and induce similar behavioral abnormalities in adult rats (Futamura et al., 2003). In this context, it is noteworthy that EGF and IL-1 α exert common effects on physical development of rats and mice, such as accelerating eyelid opening and tooth eruption (Futamura et al., 2003; Tsuda et al., 2005). Therefore, a similar pathologic mechanism may underlie the cognitive and behavioral impairments induced by neonatal EGF and IL-1 α treatment, although the responsible pathological nature of the rats treated with these cytokines as neonates remains to be characterized.

Abnormal inflammatory cytokine signals are often detected in patients with various psychiatric diseases including schizophrenia (Licinio et al., 1993; Katila et al., 1994;

Mittleman et al., 1997; Lin et al., 1998; Toyooka et al., 2003). Although it is unclear whether elevated cytokine levels in these patients result from their pathologic condition or have etiologic implications, prior epidemiologic investigations propose the involvement of inflammatory cytokines in abnormal brain development or later behavioral/cognitive impairment (Nawa et al., 2000; Nawa and Takei, 2006). Viral infection or abnormal parturition can increase the levels of endogenous inflammatory cytokines by greater than 100-fold in amniotic fluid (Romero et al., 1990; Tsunoda et al., 1990; Halgunset et al., 1994) and are risk factors for schizophrenia (O'Callaghan et al., 1991, 1992; Fatemi et al., 2002a; Shi et al., 2003). Maternal immune responses are transmitted through the placental barrier and induce IL-1 β and other cytokines in embryos (Cai et




Fig. 10. Effects of delayed IL-1 α treatment on startle responses as adults. The rats used in Fig. 9 were subjected to the same startle tests at 8 weeks of age. (a) Absolute amplitudes of the 120-dB acoustic startle of rats treated with vehicle (open circle, $n=10$) and IL-1 α (closed circle, $n=10$) were monitored in the absence and presence of prepulse stimuli (none, 75, 80, and 85 dB). (b) Absolute magnitudes of PPI were calculated and compared between vehicle-treated (open bar) and IL-1 α -treated (closed bar) animals. (c) Percentage PPI was calculated and compared between vehicle- and IL-1 α -treated animals. Data represent means \pm S.E.M.

al., 2000; Zuckerman et al., 2003; Meyer et al., 2006c). It is therefore possible that after maternal inflammation, infection, or obstetric complication, fetuses are exposed to concentrations of IL-1 or other inflammatory cytokines high enough to perturb brain development (Cai et al., 2000;




Fig. 11. Learning ability of IL-1 α -treated rats. Learning in rats treated as neonates with IL-1 α was assessed by active-avoidance response, contextual conditioning, and a radial arm maze task from PND56 to PND70. (a) The mean value (\pm S.E.M.) of percent avoidance response in active-avoidance test for control (open circle, $n=9$) and IL-1 α -treated rats (closed circle, $n=9$) was determined at PND56–65. (b) Mean percentage (\pm S.E.M.) of freezing time of vehicle-treated (open circle, $n=15$) and IL-1 α -treated rats (closed circle, $n=15$) was scored for 3 min before and 1 day after conditioning stimuli (arrows). (c) Spatial reference was scored in the eight-arm radial maze task. The number of errors was averaged over three sessions and compared between control (open circle, $n=10$) and IL-1 α -treated rats (closed circle, $n=10$).




Fig. 12. Absence of gross neuropathological abnormality in the adult brain of IL-1 α -treated animals. Sections from the cortex (a, b), hippocampus (c, d), striatum (e, f) and cerebellum (g, h) of rats treated with PBS (control; a, c, e, g) or IL-1 α as neonates (b, d, f, h) were examined at PND60 with the Kluver-Barrera stain. Hematoxylin/eosin staining of the CA1 pyramidal layer and Purkinje layer is shown in the inset. Staining revealed no apparent differences in sections from three animals. Scale bars=1.0 mm in c, d, g, h and 0.1 mm in a, b, e, f.

Borrell et al., 2002; Fatemi et al., 2002b; Zuckerman et al., 2003). A similar mechanism may contribute to the neurobehavioral impairments in other animal models of schizophrenia as brain injury and psychostimulants also induce IL-1 (Ho and

Blum, 1998; Touzani et al., 1999; Jankowsky and Patterson, 2001; Wang et al., 2001; Lipska et al., 2002). In this context, it is noteworthy that reductions in dopamine receptors and GAD67, which were observed in the present

IL-1 model, have been implicated in the neuropathology associated with schizophrenia (Akbarian et al., 1995; Okubo et al., 1997; Hakak et al., 2001). Although we failed to detect significant difference in these phenotypic markers at the adult stage, we cannot rule out the possibility that such neurochemical abnormality might persist in limited brain region(s) until adulthood.

A postmortem study indicates higher vulnerability of IL-1-mediated neuroinflammatory reactions in schizophrenia patients (Toyooka et al., 2003) and genetic investigations point out the association of the IL-1 gene complex and the risk of this illness (Katila et al., 1999; Meisenzahl et al., 2001; Zanardini et al., 2003). Both results suggest a potential biological link between IL-1-triggered neuroinflammatory processes and schizophrenia etiology or pathology. A variety of cytokines interacts with IL-1 α in such neuropathological conditions (Hornig et al., 1999; Jankowsky and Patterson, 2001; Watanabe et al., 2003; Meyer et al., 2006b,c). It is possible that IL-1 affects the production and signaling of neurotrophic molecules such as BDNF and indirectly influences neurobehavioral development as well as psychopathological traits (Tong et al., 2007; Angelucci et al., 2005). In this context, neuropathological functions and neurobehavioral impact of other cytokines in prenatal and postnatal immune-inflammatory processes remain to be characterized. The present animal experiments indicate that, when immune inflammatory reactions occur and induce IL-1 α at embryonic or early postnatal stages, this cytokine reaches immature brain and impairs later development of sensorimotor gating. In humans, under analogous circumstances, IL-1 and other inflammatory cytokine may contribute to the risk of developing schizophrenia or other psychobehavioral impairments.

Acknowledgments—This work was supported by grants-in-aid for Creative Scientific Research and Basic Scientific Research (B), the Health and Labor Sciences Research Grants, Research Project Grants from Niigata University, and Core Research for Evolutional Science and Technology from the JST Corporation. We are also grateful to Dainippon Pharmaceuticals Inc. for recombinant IL-1 α .

REFERENCES

- Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE Jr, Jones EG (1995) Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. *Arch Gen Psychiatry* 52:258–266.
- Angelucci F, Brene S, Mathe AA (2005) BDNF in schizophrenia, depression and corresponding animal models. *Mol Psychiatry* 10:345–352.
- Anisman H, Merali Z (2003) Cytokines, stress and depressive illness: brain-immune interactions. *Ann Med* 35:2–11.
- Banks WA, Farr SA, Morley JE (2002–2003) Entry of blood-borne cytokines into the central nervous system: effects on cognitive processes. *Neuroimmunomodulation* 10:319–327.
- Bonni A, Sun Y, Nadal-Vicens M, Bhatt A, Frank DA, Rozovsky I, Stahl N, Yancopoulos GD, Greenberg ME (1997) Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. *Science* 278:477–483.
- Borrell J, Vela JM, Arevalo-Martín A, Molina-Holgado E, Guaza C (2002) Prenatal immune challenge disrupts sensorimotor gating in adult rats. Implications for the etiopathogenesis of schizophrenia. *Neuropsychopharmacology* 26:204–215.
- Braff DL, Geyer MA (1990) Sensorimotor gating and schizophrenia: Human and animal model studies. *Arch Gen Psychiatry* 47:181–188.
- Cadenhead KS, Geyer MA, Braff DL (1993) Impaired startle prepulse inhibition and habituation in patients with schizotypal personality disorder. *Am J Psychiatry* 150:1862–1867.
- Cai Z, Pan ZL, Pang Y, Evans OB, Rhodes PG (2000) Cytokine induction in fetal rat brains and brain injury in neonatal rats after maternal lipopolysaccharide administration. *Pediatr Res* 47:64–72.
- Cannon M, Jones PB, Murray RM (2002) Obstetric complications and schizophrenia: historical and meta-analytic review. *Am J Psychiatry* 159:1080–1092.
- Dantzer R, Kelley KW (2007) Twenty years of research on cytokine-induced sickness behavior. *Brain Behav Immun* 21:153–160.
- Fatemi SH, Earle J, Kanodia R, Kist D, Emamian ES, Patterson PH, Shi L, Sidwell R (2002a) Prenatal viral infection leads to pyramidal cell atrophy and macrocephaly in adulthood: implications for genesis of autism and schizophrenia. *Cell Mol Neurobiol* 22:25–33.
- Fatemi SH, Emamian ES, Sidwell RW, Kist DA, Sary JM, Earle JA, Thuras P (2002b) Human influenza viral infection in utero alters glial fibrillary acidic protein immunoreactivity in the developing brains of neonatal mice. *Mol Psychiatry* 7:633–640.
- Fatemi SH, Pearce DA, Brooks AI, Sidwell RW (2005) Prenatal viral infection in mouse causes differential expression of genes in brains of mouse progeny: a potential animal model for schizophrenia and autism. *Synapse* 57:91–99.
- Futamura T, Kakita A, Tohmi M, Sotoyama H, Takahashi H, Nawa H (2003) Neonatal perturbation of neurotrophic signaling results in abnormal sensorimotor gating and social interaction in adults: implication for epidermal growth factor in cognitive development. *Mol Psychiatry* 8:19–29.
- Gayle DA, Belooesky R, Desai M, Amidi F, Nunez SE, Ross MG (2004) Maternal LPS induces cytokines in the amniotic fluid and corticotropin releasing hormone in the fetal rat brain. *Am J Physiol Regul Integr Comp Physiol* 286:R1024–R1029.
- Grillon C, Ameli R, Charney DS, Krystal J, Braff D (1992) Startle gating deficits occur across prepulse intensities in schizophrenic patients. *Biol Psychiatry* 32:939–943.
- Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA (2001) Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. *Proc Natl Acad Sci U S A* 98:4746–4751.
- Haugset J, Johnsen H, Kjollesdal AM, Qvigstad E, Espevik T, Austgulen R (1994) Cytokine levels in amniotic fluid and inflammatory changes in the placenta from normal deliveries at term. *Eur J Obstet Gynecol Reprod Biol* 56:153–160.
- Ho A, Blum M (1997) Regulation of astroglial-derived dopaminergic neurotrophic factors by interleukin-1 beta in the striatum of young and middle-aged mice. *Exp Neurol* 148:348–359.
- Ho A, Blum M (1998) Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease. *J Neurosci* 18:5614–5629.
- Hornig H, Weissenböck N, Horscroft, Lipkin WI (1999) An infection-based model of neurodevelopmental damage. *Proc Natl Acad Sci U S A* 96:12102–12107.
- Jankowsky JL, Patterson PH (2001) The role of cytokines and growth factors in seizures and their sequelae. *Prog Neurobiol* 63:125–149.
- Jentsch JD, Tran A, Le D, Youngren KD, Roth RH (1997) Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. *Neuropsychopharmacology* 17:92–99.
- Katila H, Appelberg B, Hurme M, Rimon R (1994) Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders. *Schizophr Res* 12:29–34.

- Katila H, Hanninen K, Hume M (1999) Polymorphisms of the interleukin-1 gene complex in schizophrenia. *Mol Psychiatry* 4:179–181.
- Kim IJ, Beck HN, Lein PJ, Higgins D (2002) Interferon gamma induces retrograde dendritic retraction and inhibits synapse formation. *J Neurosci* 22:4530–4539.
- Kleshcheva RP (1988) The development of components of the blood-brain barrier in the neocortex of the white rat. *Arkh Anat Gistol Embriol* 95:22–26.
- Li Y, Liu L, Barger SW, Griffin WS (2003) Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. *J Neurosci* 23:1605–1611.
- Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH (1993) Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. *Am J Psychiatry* 150:1408–1410.
- Licinio J, Wong ML (1999) The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. *Mol Psychiatry* 4:317–327.
- Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, Pioli R, Altamura C, Scharpe S, Maes M (1998) The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. *Schizophr Res* 32:9–15.
- Ling ZD, Potter ED, Lipton JW, Carvey PM (1998) Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines. *Exp Neurol* 149:411–423.
- Lipska BK, Aultman JM, Verma A, Weinberger DR, Moghaddam B (2002) Neonatal damage of the ventral hippocampus impairs working memory in the rat. *Neuropsychopharmacology* 27:47–54.
- McLay RN, Kastin AJ, Zadina JE (2000) Passage of interleukin-1 β across the blood-brain barrier is reduced in aged mice: A possible mechanism for diminished fever in aging. *Neuroimmunomodulation* 8:148–153.
- Meisenzahl EM, Rujescu D, Kirner A, Giegling I, Kathmann N, Leisinger G, Maag K, Hegerl U, Hahn K, Moller HJ (2001) Association of an interleukin-1beta genetic polymorphism with altered brain structure in patients with schizophrenia. *Am J Psychiatry* 158:1316–1319.
- Meyer U, Schwendener S, Feldon J, Yee BK (2006a) Prenatal and postnatal maternal contributions in the infection model of schizophrenia. *Exp Brain Res*, in press.
- Meyer U, Nyffeler M, Engler A, Urwyler A, Schedlowski M, Knuesel I, Yee BK, Feldon J (2006b) The time of prenatal immune challenge determines the specificity of inflammation-mediated brain. *J Neurosci* 26:4752–4762.
- Meyer U, Feldon J, Schedlowski M, Yee BK (2006c) Immunological stress at the maternal-foetal interface: a link between neurodevelopment and adult psychopathology. *Brain Behav Immun* 20:378–388.
- Minami M, Kuraishi Y, Yamaguchi T, Nakai S, Hirai Y, Satoh M (1991) Immobilization stress induces interleukin-1 beta mRNA in the rat hypothalamus. *Neurosci Lett* 123:254–256.
- Minami M, Kuraishi Y, Yabuuchi K, Yamazaki A, Satoh M (1992) Induction of interleukin-1 beta mRNA in rat brain after transient forebrain ischemia. *J Neurochem* 58:390–392.
- Mittleman BB, Castellanos FX, Jacobsen LK, Rapoport JL, Swedo SE, Shearer GM (1997) Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. *J Immunol* 159:2994–2999.
- Mizuno M, Yamada K, Oiaru A, Nawa H, Nabeshima T (2000) Involvement of brain-derived neurotrophic factor in spatial memory formation and maintenance in a radial arm maze test in rats. *J Neurosci* 20:7116–7121.
- Muller N, Ackenheil M (1998) Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. *Prog Neuropsychopharmacol Biol Psychiatry* 22:1–33.
- Murphy BL, Amsten AF, Goldman-Rakic PS, Roth RH (1996) Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. *Proc Natl Acad Sci U S A* 93:1325–1329.
- Nawa H, Takahasi M, Patterson PH (2000) Cytokine and growth factor involvement in schizophrenia-support for the development model. *Mol Psychiatry* 5:594–603.
- Nawa H, Carnahan J, Gall C (1995) BDNF protein measured by a novel enzyme immunoassay in normal brain and after seizure: partial disagreement with mRNA levels. *Eur J Neurosci* 7:1527–1535.
- Nawa H, Takei N (2006) Recent progress in animal modeling of immune inflammatory processes in schizophrenia: Implication of specific cytokines. *Neurosci Res* 56:2–13.
- O'Callaghan E, Sham P, Takei N, Glover G, Murray RM (1991) Schizophrenia after prenatal exposure to 1957 A2 influenza epidemic. *Lancet* 337:1248–1250.
- O'Callaghan E, Gibson T, Colohan HA, Buckley P, Walshe DG, Larkin C, Waddington JL (1992) Risk of schizophrenia in adults born after obstetric complications and their association with early onset of illness: a controlled study. *BMJ* 305:1256–1259.
- Ohno M, Frankland PW, Chen AP, Costa RM, Silva AJ (2001) Inducible, pharmacogenetic approaches to the study of learning and memory. *Nat Neurosci* 4:1238–1243.
- Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. *Nature* 385:634–636.
- Papiol S, Molina V, Desco M, Rosa A, Reig S, Gispert JD, Sanz J, Palomo T, Fananas L (2005) Ventricular enlargement in schizophrenia is associated with a genetic polymorphism at the interleukin-1 receptor antagonist gene. *Neuroimage* 27:1002–1006.
- Pluss C, Werner ER, Blau N, Wächter H, Pfeilschifter J (1996) Interleukin 1 beta and cAMP trigger the expression of GTP cyclohydrolase I in rat renal mesangial cells. *Biochem J* 318:665–671.
- Proescholdt MG, Chakravarty S, Foster JA, Foti SB, Briley EM, Herkenham M (2002) Intracerebroventricular but not intravenous interleukin-1 β induces widespread vascular-mediated leukocyte infiltration and immune signal mRNA expression followed by brain-wide glial activation. *Neuroscience* 112:731–749.
- Romero R, Avila C, Santhanam U, Sehgal PB (1990) Amniotic fluid interleukin 6 in preterm labor. Association with infection. *J Clin Invest* 85:1392–1400.
- Rothwell NJ, Luheshi GN (2000) Interleukin 1 in the brain: Biology, pathology and therapeutic target. *Trends Neurosci* 23:618–625.
- Sarandakou A, Giannaki G, Malamitsi-Puchner A, Rizos D, Hourdaki E, Protonotariou E, Phocas I (1998) Inflammatory cytokines in newborn infants. *Mediators Inflamm* 7:309–312.
- Shi L, Fatemi SH, Sidwell RW, Patterson PH (2003) Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. *J Neurosci* 23:297–302.
- Shi L, Tu N, Patterson PH (2005) Maternal influenza infection is likely to alter fetal brain development indirectly: the virus is not detected in the fetus. *Int J Dev Neurosci* 23:299–305.
- Swerdlow NR, Geyer MA (1998) Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. *Schizophr Bull* 24:285–301.
- Swerdlow NR, Braff DL, Geyer MA (2000) Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. *Behav Pharmacol* 11:185–204.
- Tohmi M, Tsuda N, Watanabe Y, Kakita A, Nawa H (2004) Perinatal inflammatory cytokine challenge results in distinct neurobehavioral alterations in rats: implication in psychiatric disorders of developmental origin. *Neurosci Res* 50:67–75.
- Tong L, Balazs R, Soiaipornkul R, Thangnipon W, Cotman CW (2007) Interleukin-1beta impairs brain derived neurotrophic factor-induced signal transduction. *Neurobiol Aging*, Apr 26 [Epublication]. doi: 10.1016/j.neurobiolaging.2007.02.027.